22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
25
Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines.
Sun Yat-Sen University
7
Design, synthesis, and antitumor activity of NSDs inhibitors targeting lung squamous cell carcinoma.
Peking University
32
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors.
Ocean University of China
21
Rational fragment-based design of compounds targeting the PWWP domain of the HRP family.
KU Leuven
31
Inhibitors targeting the PWWP domain-containing proteins.
Central China Normal University
2
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
University of Cambridge
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
40
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
29
Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
China Pharmaceutical University
36
Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors.
University of Chinese Academy of Sciences
25
Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Jiangsu University of Technology
2
Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches.
AstraZeneca
20
Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
China Pharmaceutical University
18
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Peking University
33
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
University of Texas Medical Branch (UTMB)
1
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
Shanghai Institute of Materia Medica
47
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
30
From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).
University of S£O Paulo
39
Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
Chinese Academy of Sciences
44
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
6
Fragment-to-Lead Medicinal Chemistry Publications in 2019.
Novartis Institutes For Biomedical Research
